Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes a situation where counterparties are already losing something real and ongoing as long as they do not have what the company provides, and that this is visible in their behavior. The essence is a running meter on the other side. We need to scan the transcript for such descriptions. Management talks about NanoKnife, Auryon, AlphaVac, AngioVac, etc. Look for language about customers incurring costs or losses while waiting, or behaving urgently. In the transcript, Jim Clemmer mentions: "The interest and desire for focal therapy continues to build with both patients and physicians. We believe that NanoKnife will be the best option..." That's not a running meter. For Auryon: "We continue to gain share because physicians are gaining confidence..." Not a meter. For AlphaVac: "We have been very pleased with the clinical feedback... physicians tell us that the intuitive design allows for safe and effective clot removal..." Not a meter. He mentions "physicians are looking for new treatment options that better preserve their quality of life." That's a desire but not a running cost. What about the potential market? "We believe that NanoKnife has the potential to open up a roughly $700 million market..." That's future. Management talks about international growth, but not about counterparties currently losing something. Steve Trowbridge talks about backlog, cash, etc. The question specifically asks: "does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING ... FOR AS LONG AS THEY DO NOT HAVE WHAT THIS COMPANY PROVIDES, and that this accumulating loss on the other side is ALREADY VISIBLE in how those parties are behaving toward the company today?" I see no such description. The company is pushing its products, highlighting benefits, growth, clinical data, but not saying that customers are incurring costs or losses because they lack the product. There is no mention of customers pressing for delivery, accepting worse terms, etc. The only urgency is from the company's own perspective to launch new products. Thus the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...